GLP-1 receptor agonists may prevent progression to stage IV in certain obesity-related cancers, with potential to impact treatment strategies.
- In the news
Diabetes Treatment and Management
Moving in Annals of Internal Medicine, BMJ, Cancer Discovery, Cell Metabolism.
- Moved this week
- 4
Rebuilt
Moved this week
Semaglutide improves liver health in mice with MASH through intrahepatic sinusoidal endothelial GLP-1 receptors, independent of weight loss, with a substantial effect on fibrosis and immune remodeling.
- 25 cites
Latest in Diabetes Treatment and Management
Newest first · last 60 days
DD01 significantly reduces liver fat by at least 30% in 76% of adults with MASH or MASLD after 12 weeks, outperforming placebo in a phase 2 trial.
Semaglutide reduces vascular resistance and prevents fibrosis in kidneys, supporting kidney function preservation in type 2 diabetes with chronic kidney disease.
- Open access
Multidisciplinary heart-liver co-management improves detection and treatment of MASLD, addressing a critical gap in cardiometabolic care with potential to reduce mortality.
Methodological strategies like pragmatic trials and target trial emulation improve real-world evidence for GLP-1 receptor agonists, addressing key gaps in clinical practice and policy.
- 1 cites
Glucagon-like peptide-1 receptor agonists increase the 18-month risk of ischemic optic neuropathy by approximately 3 to 3.6 cases per 10,000 patients compared to other diabetes medications.
Use of GLP-1 receptor agonists is associated with a nearly twofold increased risk of anterior ischemic optic neuropathy in type 2 diabetes patients, but absolute risk remains small.
Robust real-world evidence is essential to optimize GLP-1 receptor agonist use and inform policy decisions amid expanding indications and diverse populations.
- Open access
- 1 cites
Effective obesity treatments, including new medications and procedures, are available but have not significantly reduced obesity rates in the US, which remain stable.
Once-weekly survodutide significantly reduces body weight by approximately 12-13% in adults with obesity without diabetes, outperforming placebo in a phase 3 trial.
- Open access
- 18 cites
Adding tirzepatide to standard care reduces one-year risk of major adverse cardiovascular events by 1.4% in patients with type 2 diabetes and established atherosclerotic disease.
- Open access
- 1 cites
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4